Bigora Sian 4

What Happened
Bigora Sian, Chief Development Officer of Processa Pharmaceuticals, reported an acquisition of 1,799 shares on 2026-04-15. The shares were acquired at $2.97 each for a total reported value of $5,343. The transaction is coded as a purchase (P), reported as an open-market or private purchase.

Key Details

• Transaction date and price: 2026-04-15 at $2.97 per share.
• Total acquired: 1,799 shares; total value: $5,343.
• Filing date: 2026-04-17 (appears to be timely under Form 4 rules).
• Shares owned after transaction: not specified in the provided Form 4.
• Transaction code: P = Purchase (open market or private purchase). No footnotes, 10b5-1 plan, or tax-withholding details were provided.

Context
Insider purchases can be informative because they increase insider ownership, but this is a relatively small-dollar purchase and should be weighed alongside other insider activity and company fundamentals. The filing is factual and does not indicate motivation.